Guides, research, and insights from FemPeptides — Peptide Therapy for Women
60 articlesA pilot study showed 80-100% symptom resolution in 10 of 12 women with interstitial cystitis using oral BPC-157. What the data shows and what comes next.
How the estrobolome connects gut health to estrogen metabolism, why women get more gut disorders, and how BPC-157 and KPV support the gut-hormone axis.
How to use GHK-Cu for skin: topical vs injectable, DIY preparation from research-grade, commercial serums, and why it matters during perimenopause.
How Foundayo compares to Wegovy, Zepbound, and research GLP-1s for women: dosing convenience, weight loss data, birth control interactions, and cost.
How anti-inflammatory peptides like BPC-157 and KPV relate to endometriosis pathology: mechanisms, limitations, and what to discuss with your doctor.
How BPC-157 and GHK-Cu may support C-section recovery: wound healing, scar remodeling, adhesion prevention, and a practical timeline for postpartum peptide use.
New to peptides? Start here. The 5 peptides every woman should know, 3 ways to access them, a no-injection starter stack, and where to source safely.
How estrogen decline causes joint pain, which peptides (BPC-157, TB-500, GHK-Cu, KPV) address the tissue repair gap, and when to talk to your doctor.
75% experience hot flashes. $22B annual productivity loss. 70% can't define perimenopause. Data-driven infographic mapping every symptom to the peptide that addresses it.
Nobody talks about real costs. Full breakdown: consultations, labs, peptides by tier, supplies, monitoring. Comparison across protocol levels with monthly and annual estimates.
Your peptide priorities shift with your hormones. A decade-by-decade guide with recommended stacks, hormone trajectory charts, and cost estimates for each life stage.
70% of drugs pulled from market had greater health risks for women. Women experience 1.5-1.7x more ADRs. The safety data gap in the peptide space — visualized.
The peptide market will nearly double to $295B by 2033. Women 50-64 are the highest GLP-1 user demographic. Yet market analysis barely acknowledges women's health applications.
Only 41% of clinical trial participants are women. 80% of preclinical studies use male mice. The peptide industry was built for men. Here's the data — and why FemPeptides exists.
From Phase 3 RCTs to Reddit anecdotes. Learn to evaluate peptide claims critically. Every FemPeptides-covered peptide mapped to its evidence level with a visual ladder.
Women metabolize peptides differently than men. Estrogen modulates GH secretion. Body composition differs. A guide to sex-specific dosing adjustments with comparison charts.
84% of women's health content removed from Meta. 66% from Google. ED content proliferates freely. The censorship data that explains why women can't find peptide information.
Deep science on why female biology responds differently. Estrogen enhances B-cells, the X chromosome carries more immune genes, and hormonal cycles create variable peptide response
New to peptides? This beginner's guide explains what peptides are, how they work, which ones are FDA-approved vs research-stage, and how to get started safely — written for women
Collagen drops 30% in 5 years post-menopause. An evidence-based guide to skin peptides — GHK-Cu for remodeling, SNAP-8 for expression lines, Glutathione for brightening and oxida
IBS is 2x more common in women. An evidence-based guide to gut-healing peptides — BPC-157 for barrier repair, KPV for inflammation, and the gut-brain axis connection.
Kisspeptin-54 achieved 23-37% pregnancy rates in IVF trials with zero cases of ovarian hyperstimulation syndrome. An evidence-based guide for women exploring peptide-assisted ferti
If you're exhausted despite sleeping 8 hours, the problem may be mitochondrial. NAD+, SS-31, MOTS-C, and CJC-1295/Ipa target energy production at the cellular level.
80% of autoimmune patients are female. An evidence-based guide to Thymosin Alpha-1, KPV, LL-37, and BPC-157 for immune modulation — covering lupus, RA, IBD, Hashimoto's, and more
1 in 10 women has PCOS. An evidence-based stacking guide covering insulin resistance (MOTS-C, semaglutide), hormonal regulation (Kisspeptin-10), and the emerging research pipeline.
Not all peptides require needles. A guide to oral BPC-157, collagen peptides, sublingual options, and how bioavailability affects your results.
Don't buy peptides without checking the COA. Learn how to read HPLC purity, mass spectrometry verification, endotoxin testing, and sterility — so you know exactly what you're put
The FDA's Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to review BPC-157, TB-500, KPV, MOTS-C, DSIP, Semax, and Epitalon for 503A compounding. Here's what women n
Step-by-step guide to peptide reconstitution and subcutaneous injection, written for women. Covers supplies, dosing math, injection sites, storage, and common mistakes.
TRIUMPH-1 Phase 3 data shows retatrutide achieved up to 30.3% average weight loss. Analysis of what the triple agonist means for women — menopause, HRT synergy, and the GLP-1 lan
Evidence-based overview of peptides relevant to postpartum recovery. Covers tissue repair (BPC-157, TB-500), collagen restoration (GHK-Cu), energy (NAD+), and safety considerations
An evidence-based guide to peptides for perimenopause. Covers hot flashes, brain fog, weight gain, sleep, and mood — mapped to specific peptides with PubMed citations. Written fo
ENDO-205, the first targeted peptide therapeutic for endometriosis, received FDA IND clearance in March 2026. What this means for the 190 million women affected worldwide.
Evidence-based guide to peptides for anxiety and sleep in women. Selank showed anxiolytic effects comparable to benzodiazepines. DSIP enhances delta-wave deep sleep. PubMed-cited.
How to build a comprehensive menopause peptide protocol. Covers GH axis, metabolic support, skin/collagen, mood/sleep, and libido — with specific peptide recommendations for each
Practical guide to finding a qualified peptide therapy provider. Covers credentials, red flags, telehealth vs in-person, what to expect from your first visit, and questions to ask.
A 2024 pilot study showed BPC-157 bladder injections resolved symptoms in 10 of 12 women with severe interstitial cystitis. What this means, what the limitations are, and what's ne
Both target fat metabolism. One has FDA approval. The other avoids full GH effects. Here's the head-to-head comparison for menopausal belly fat.
Semaglutide targets GLP-1 alone. Retatrutide adds GIP and glucagon receptors for triple-agonist action. Here's how they compare for women's weight management and PCOS.
Selank targets anxiety through GABA/serotonin modulation. DSIP targets sleep through delta-wave promotion. Here's when to use each — and when to stack them together.
NAD+ fuels mitochondrial energy. Epitalon maintains telomere length. Both target cellular aging — through different mechanisms. Here's how they compare and why many women use bot
The right peptides change as your body changes. Here's a decade-by-decade guide — 40s (perimenopause), 50s (menopause), 60s+ (longevity) — with specific peptide recommendations
Women lose up to 50% of hair density by age 50. GHK-Cu reduces DHT conversion, boosts collagen in follicles, and influences 4,000+ genes. A 2026 review calls it the top peptide for
80% of autoimmune patients are female. KPV — a potent anti-inflammatory tripeptide — inhibits NF-κB signaling and modulates gut-immune axis dysfunction. Here's the evidence fo
A landmark study used kisspeptin-54 as an IVF trigger and produced 73 healthy babies with zero cases of ovarian hyperstimulation syndrome. Here's what every woman considering ferti
Epitalon reactivates telomerase, extends telomere length, and restores melatonin production from the pineal gland. It targets 5 hallmarks of aging simultaneously. Here's the eviden
The most prescribed peptide combination in functional medicine. CJC-1295/Ipamorelin restores growth hormone pulsing for sleep, body composition, skin, and the brain fog of perimeno
Anxiety disorders are 2x more prevalent in women. Selank modulates GABA and serotonin without sedation, dependence, or cognitive impairment. Here's the evidence for the anxiolytic
Menopause affects multiple systems simultaneously — so effective peptide protocols often combine multiple compounds. Here are 5 evidence-informed stacking frameworks organized by
Not all peptide suppliers are created equal. Here's how to read a COA, what to look for in a vendor, which side effects are normal vs concerning, and what bloodwork to monitor.
Menopause belly fat isn't a willpower issue — it's hormonal biology. Tesamorelin (FDA-approved), AOD-9604, and MOTS-C target visceral fat through mechanisms diet alone can't reac
Perimenopause insomnia is brutal — and melatonin often isn't enough. DSIP (Delta Sleep-Inducing Peptide) promotes the slow-wave deep sleep that hormonal changes disrupt.
PT-141 (Vyleesi) is the only FDA-approved on-demand treatment for low sexual desire in women. It works on the brain, not blood flow. Phase 3 trials with 1,200+ women. Here's everyt
NAD+ decline accelerates at 45 — right when perimenopause hits. The result is a double energy crisis: estrogen drops AND cellular energy drops. Here's how NAD+ addresses the fati
Glutathione depletion accelerates during menopause — driving visible aging, hyperpigmentation, and oxidative damage. Here's how the body's master antioxidant supports skin bright
Women lose 30% of their collagen in the first 5 years after menopause. GHK-Cu — a naturally occurring copper peptide — stimulates collagen production, supports hair growth, and
IBS is 2x more common in women. A pilot study showed 10 of 12 women with interstitial cystitis achieved 80-100% symptom resolution with BPC-157. Here's the complete evidence review
An evidence-based review of peptides for polycystic ovary syndrome — Kisspeptin-10, MOTS-C, Semaglutide, BPC-157, and NAD+. PubMed-cited. Written for women.
HRT addresses sex hormone deficiency. Peptides target the parallel axes — growth hormone, tissue repair, immune signaling — that estrogen replacement alone doesn't cover.
A complete timeline of the FDA's peptide reclassification — from the 2023 Category 2 restrictions to the April 2026 removal of 12 peptides and the upcoming July PCAC review.
No articles found matching your search.